RxDoctor Payments Data

Matthew Bruneau, MD

Family Medicine · Trinity, FLNPI 1023200961

Payments from drug & device makers

$1,963in general payments, 2019–2025

Across 111 payments — averaging $17.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$545
  • AbbVie$250
  • Abbott$114
  • Amgen$110
  • Boehringer Ingelheim$109
  • Esperion Therapeutics, Inc.$108
  • plus $728 from 15 others

What the payments were for

  • Food & beverage$1,963100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,963 in reported general payments places this provider in the 75th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$128,592
Medicare patients
283
Services billed
1,261

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide79$109,155
JardianceEmpagliflozin81$72,858
Trelegy ElliptaFluticasone/Umeclidin/Vilanter71$67,273
EliquisApixaban72$63,896
TrulicityDulaglutide57$58,505
MounjaroTirzepatide24$23,921
TradjentaLinagliptin14$20,508
MyrbetriqMirabegron24$18,193
XareltoRivaroxaban13$17,655
RybelsusSemaglutide12$16,868
Breo ElliptaFluticasone/Vilanterol20$10,228
Spiriva RespimatTiotropium Bromide17$8,908
Repatha SyringeEvolocumab12$7,909
Advair HfaFluticasone Propion/Salmeterol25$7,719
Rosuvastatin Calcium453$7,516

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$545$126,02391 claims
Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat, Stiolto Respimat$109$109,685128 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$32$84,097105 claims
Lilly USA, LLCTrulicity, Mounjaro$104$82,42681 claims
PfizerEliquis$93$63,89672 claims
Johnson & JohnsonXarelto$14$17,65513 claims
AbbVieSynthroid$250$3,55050 claims
Sanofi-aventis U.S. LLCLantus$22$1,83517 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Trinity

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →